DLBCL
Novel Agents Expand Rx for Refractory Lymphoma
Treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma have increased dramatically, ...
MAY 29, 2022
Large Study Suggests Possible New Standard for Previously Treated DLBCL
A new drug regimen containing the antibody-drug conjugate polatuzumab vedotin-piiq is challenging the previous ...
FEBRUARY 11, 2022
FDA Approves Rituxan Plus Chemotherapy for Pediatric Hematologic Cancers
The FDA approved rituximab (Rituxan, Genentech) in combination with chemotherapy for pediatric patients (≥6 ...
DECEMBER 8, 2021
Zynlonta Approved for Relapsed or Refractory Large B-Cell Lymphomas
The FDA granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics) for the treatment ...
MAY 5, 2021
FDA Approves Monjuvi Plus Revlimid for DLBCL
The FDA granted accelerated approval to tafasitamab-cxix (Monjuvi, MorphoSys US/Incyte) in combination with ...
AUGUST 7, 2020
Xpovio Approved to Treat Relapsed or Refractory DLBCL
The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) for the treatment of adult patients with ...
JUNE 23, 2020
Novel Agent Found Effective in B-Cell Cancers, Even After CAR T-Cell Failure
A novel investigational bispecific antibody therapy called mosunetuzumab produced durable complete response sin ...
FEBRUARY 24, 2020
FDA Approves Polivy for Diffuse Large B-Cell Lymphoma
The FDA granted accelerated approval to polatuzumab vedotin-piiq, in combination with bendamustine and a rituximab ...
JUNE 12, 2019
R-CHOP14 and 21 Equally Safe and Effective for DLBCL
Fourteen- and 21-day cycles of R-CHOP are similarly safe and effective in the treatment DLBCL, according data ...
NOVEMBER 15, 2018
CAR T-Cell Rx Effective in Refractory Lymphoma
Chicago—In patients with refractory diffuse large B-cell lymphoma (DLBCL), response rates with axicabtagene ...
OCTOBER 3, 2018
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
CTL019 Receives Breakthrough Designation for Relapsed/Refractory DLBCL
The drug was granted breakthrough therapy designation for the treatment of adult patients with r/r diffuse large ...
APRIL 18, 2017